Currently, there are 70 suspected cases of acute hepatitis in Indonesia.
REPUBLIKA.CO.ID, JAKARTA – Spokesperson for the Indonesian Ministry of Health (Kemenkes) Mohammad Syahril revealed, until Friday (6/24/2022) the suspected case hepatitis acute cases in Indonesia recorded 70 cases. He also revealed that the most common pathogens were Cytomegalovirus (CMV).
Cumulatively, there are currently 70 cases of hepatitis in Indonesia, spread across 21 provinces. Of the 70 cases, 16 are probable, 14 are pending, and 40 are discarded.
Syahril explained that discarded meant cases that were removed because the cause was known and not from the hepatitis group. The most common symptoms experienced by patients were fever, nausea, vomiting, and jaundice.
“From PCR and metagenomic examinations of 16 probable pathogens, it is known that the most common pathogen found in portable patients is cytomegalovirus (CMV), namely 4 of the 15 patients examined,” he said at an online press conference in Jakarta, Friday (24/6/2022).
Then 9 of the 16 probable patients who had PCR and metagenomic examination detected viruses from the herpesviridae family, namely CMV, HSV1, HHV-6A, HHV1, EBV. Furthermore, 1 patient was positive for enterovirus and 1 patient was positive for adenovirus.
Until now, there is no definition of hepatitis made by WHO. Dr. Syahril continued that he was still waiting for a definition such as positive PCR for COVID-19, but for this hepatitis there was still nothing called confirmation.
Distribution of suspected cases acute hepatitis it is spread in a number of these areas, North Sumatra, West Sumatra, Riau, Jambi, Bangka Belitung Islands, Banten, DKI Jakarta. Next, DI Yogyakarta, Central Java, East Java, Bali and West Nusa Tenggara. Then East Kalimantan, North Kalimantan, West Kalimantan, then South Sulawesi, North Sulawesi, West Sulawesi, Southeast Sulawesi, Central Sulawesi.
Furthermore, Syahril revealed, there were a number of symptoms encountered by the patient. One of the symptoms that are often encountered is fever which is recorded at 76.7 percent, nausea with an acquisition of 66.7 percent, then symptoms of vomiting and Jaundice at 66.7 percent.
In addition, other symptoms encountered were loss of appetite, namely 50 percent, abdominal pain at 46.7 percent, acute diarrhea, malaise and changes in urine color with gains of 33.3 percent.
Meanwhile, for changes in stool color (pale) at 23.3 percent, itching was recorded at 13.3 percent, shortness of breath at 10 percent and arthralgia/myalgia reached 6.7 percent.
–
–
